Dr. John M. Schallenkamp, MD

Dr. Schallenkamp practices at Cheyenne Regional Medical Center in Cheyenne, Wyoming, part of Laramie County Shooting Sports Complex.

Dr. Schallenkamp's NPI, 1265455018, was assigned on July 25, 2006. Dr. Schallenkamp graduated from Medical College Of Wisconsin in 2000. Dr. Schallenkamp holds Montana license 10809.

Dr. Schallenkamp's primary practice is Cheyenne Regional Medical Center, at 214 East 23rd Street, Cheyenne, WY 82001 in Laramie County. The practice phone is (307) 633-2273.

Dr. Schallenkamp's primary practice is Cheyenne Regional Medical Center in Cheyenne, Wyoming, part of Laramie County Shooting Sports Complex. Dr. Schallenkamp is also affiliated with UCHealth Poudre Valley Hospital. The medical group on file is Cheyenne Regional Medical Center. Dmand AI also links Dr. Schallenkamp to 2 more hospitals, 3 medical groups and 2 group practices and clinics, each named with a free account. Dr. Schallenkamp's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schallenkamp practices, 6 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Schallenkamp's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Schallenkamp is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Schallenkamp's licenses on file in 5 states: Montana, Colorado, Wyoming, Minnesota and Wisconsin.

Dmand AI lists bone cancer radiation, brain cancer radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, head & neck cancer radiation, lung cancer radiation and lymphoma radiation among the conditions Dr. Schallenkamp treats.

CMS data shows 1,730 Medicare services from Dr. Schallenkamp across 17 procedure codes in 2024, for 279 Medicare patients. Medicare paid $122,052 for them.

CMS counts 279 Medicare patients who saw Dr. Schallenkamp in 2024. The largest group is 65 to 74, with 144 patients. 75% of them have cancer, and 70% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Schallenkamp's median patient age at 75, with 35% women.

In 2024, Dr. Schallenkamp wrote 60 Medicare Part D claims for 32 patients. 98% of them were for generic drugs. CMS names the drug for 39 of them, across 2 drugs with 11 or more claims each, at $473 in total drug cost. In 2023, CMS named 43 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Schallenkamp for performance year 2024, reported as part of a group. Dr. Schallenkamp accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Schallenkamp as offering telehealth.

Dmand AI links 5 papers to Dr. Schallenkamp in 2024. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols and Lung Neoplasms. Dr. Schallenkamp's most frequent co-authors are Nabil Adra, MD, Edem S. Agamah, MD and Mitchell B. Alden, DO.

Dmand AI links Dr. Schallenkamp to 11 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Lung Neoplasms, Thoracic Neoplasms and Gallbladder Neoplasms. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 9 general payments to Dr. Schallenkamp from 6 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Pinnacle Biologics, Inc paid the most, $93.

Dr. Schallenkamp graduated from Medical College Of Wisconsin in 2000.

Dr. Schallenkamp is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.